Mitogen-Activated Protein Kinase 1 (MAPK1)
MAPK1 encodes mitogen-activated protein kinase 1, also known as ERK2, a serine/threonine kinase in the MAPK/ERK signaling cascade.
MAPK1 encodes mitogen-activated protein kinase 1, also known as ERK2, a serine/threonine kinase in the MAPK/ERK signaling cascade. This pathway transduces extracellular growth and stress signals from upstream regulators such as RAF and MEK to downstream effectors that control proliferation, differentiation, survival, migration, and metabolic adaptation. Because of its central position in signal transduction, MAPK1 is frequently evaluated in cancer biology and other disease contexts as a readout of pathway activation, typically through its phosphorylated form, phosphorylated ERK.
In biomedical research, MAPK1 is often studied alongside related signaling nodes including KRAS, FLT3, Protein kinase B (PKB), STAT5A, vascular endothelial growth factor A (VEGFA), and ESR1, reflecting its role in broader oncogenic and tissue-response networks. Recent studies have used MAPK1 as a mechanistic marker of pathway inhibition, a docking target in computational screening, and a candidate gene in regulatory analyses such as microRNA-target prediction. These investigations collectively reinforce MAPK1 as a key mediator of MAPK/ERK signaling in cancer, metabolic disease, and regenerative biology.
Where the papers sit
18 papers from the last 6 months study Mitogen-Activated Protein Kinase 1 (MAPK1) directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 1 observational · 2 human data · 12 preclinical · 3 unclassified
Themes no clear themes · 1 paradigm shift
Those 18 do not share a common subject.
-
MAPK1-related signaling appears alongside cancer therapeutics, pain biology, metabolism, bone loss, fibrosis, neurodegeneration and plant chemistry. Individual studies address SHP2 and RAS-ERK inhibition, cuproptosis, CGRP and NaV1.7 signaling, exosomal miR-106b-5p, and extracellular-vesicle delivery. The collection also includes CRISPR mutagenesis, systematic-review planning and molecular profiling. These topics share no coherent biological question or overall research direction.
ERK/MAPK1 blockade alone can provoke or sustain pathway escape rather than provide durable control
In pancreatic ductal adenocarcinoma, ERK inhibition induced a compensatory lipophagy–fatty-acid-oxidation program that enabled survival during KRAS-pathway blockade, while in colorectal cancer, MTPN drove noncanonical ERK activation by scaffolding ERK–MEK binding and was associated with malignancy and poor survival. Together, these findings challenge the assumption that inhibiting the canonical RAS–ERK pathway is sufficient: durable control may require cotargeting the metabolic adaptation or the alternative ERK-activating scaffold that defeats pathway inhibition 42452976Jul 42009970Apr.
Papers
The 18 papers from the last 6 months that study Mitogen-Activated Protein Kinase 1 (MAPK1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (18)
- Thiadiazolo-Triazolo-Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug development research · 19 Aug 2026 PMID 42616559
- Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine · 22 Jul 2026 PMID 42486098
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
- Multi-dimensional profiling of primary metabolites in Heuchera micrantha varieties reveals potential for functional food development. Genomics · 9 Jul 2026 PMID 42425198
- Epigallocatechin Gallate Attenuates Arecoline-induced Migration and Invasion in Esophageal Squamous Cell Carcinoma Cells Associated With EGFR/AKT/P38 Signaling. Anticancer research · 29 Jun 2026 PMID 42373249
- Deciphering protein mutation-phenotype linkages from CRISPR-based tiling mutagenesis screens. Cell systems · 26 Jun 2026 PMID 42361799
- Dual-engineered small extracellular vesicles targeted delivery miR-126 for reducing age-related bone loss. Biomedical materials (Bristol, England) · 17 Jun 2026 PMID 42309139
- Coumarin metabolites in Ocimum: chemical diversity, biosynthetic pathways, and network pharmacology-based prediction of multi-target anticancer potential. Plant molecular biology · 3 Jun 2026 PMID 42236954
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
- Structurally diverse sesquiterpenoid glucoside esters from Cissampelopsis volubilis suppress triple-negative breast cancer via RAS-ERK signaling axis. Bioorganic chemistry · 10 May 2026 PMID 42107259
- Plasma Exosomal miR-106b-5p Is Associated With Osteoporosis by Targeting SMAD5, BMP2, and MAPK1 Genes. In vivo (Athens, Greece) · 28 Apr 2026 PMID 42049413
- Bispecific targeting of CHI3L1 and PD-1 as a therapeutic strategy for pulmonary fibrosis. JCI insight · 28 Apr 2026 PMID 42048160
- Molecular lineages of sporadic mismatch-repair deficient colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 21 Apr 2026 PMID 42013404
- MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. Oncogene · 20 Apr 2026 PMID 42009970
- Yangweishu granules in treating chronic atrophic gastritis with spleen-stomach dampness-heat syndrome: An integrated study on its mechanism using multiple technologies. Journal of ethnopharmacology · 15 Apr 2026 PMID 41985642
By study type
Observational studies and case reports (1)
- Plasma Exosomal miR-106b-5p Is Associated With Osteoporosis by Targeting SMAD5, BMP2, and MAPK1 Genes. In vivo (Athens, Greece) · 28 Apr 2026 PMID 42049413
Human data, design not indexed (2)
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- Deciphering protein mutation-phenotype linkages from CRISPR-based tiling mutagenesis screens. Cell systems · 26 Jun 2026 PMID 42361799
Preclinical: animal, cell and lab studies (12)
- Thiadiazolo-Triazolo-Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug development research · 19 Aug 2026 PMID 42616559
- Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine · 22 Jul 2026 PMID 42486098
- KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
- Epigallocatechin Gallate Attenuates Arecoline-induced Migration and Invasion in Esophageal Squamous Cell Carcinoma Cells Associated With EGFR/AKT/P38 Signaling. Anticancer research · 29 Jun 2026 PMID 42373249
- Dual-engineered small extracellular vesicles targeted delivery miR-126 for reducing age-related bone loss. Biomedical materials (Bristol, England) · 17 Jun 2026 PMID 42309139
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
- Structurally diverse sesquiterpenoid glucoside esters from Cissampelopsis volubilis suppress triple-negative breast cancer via RAS-ERK signaling axis. Bioorganic chemistry · 10 May 2026 PMID 42107259
- Bispecific targeting of CHI3L1 and PD-1 as a therapeutic strategy for pulmonary fibrosis. JCI insight · 28 Apr 2026 PMID 42048160
- MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. Oncogene · 20 Apr 2026 PMID 42009970
- Yangweishu granules in treating chronic atrophic gastritis with spleen-stomach dampness-heat syndrome: An integrated study on its mechanism using multiple technologies. Journal of ethnopharmacology · 15 Apr 2026 PMID 41985642
Unclassified: not yet indexed with MeSH (3)
- Multi-dimensional profiling of primary metabolites in Heuchera micrantha varieties reveals potential for functional food development. Genomics · 9 Jul 2026 PMID 42425198
- Coumarin metabolites in Ocimum: chemical diversity, biosynthetic pathways, and network pharmacology-based prediction of multi-target anticancer potential. Plant molecular biology · 3 Jun 2026 PMID 42236954
- Molecular lineages of sporadic mismatch-repair deficient colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 21 Apr 2026 PMID 42013404
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.